Abstract
Intracerebral hemorrhage (ICH) is a devastating form of stroke, with substantial mortality and morbidity. Hemorrhage expansion (HE) occurs in ~40% of patients and portends worse neurologic outcome and mortality. Currently, ICH patients are admitted to the intensive care unit (ICU) and monitored for HE with neurologic exam and neuroimaging. By the time a change is detected, it may be too late to mitigate HE. There is a clinical need for a non-invasive bedside monitor of ICH.
The SENSE consists of a 9-antenna array mounted around the head with driving electronics. A 913 MHz signal is transmitted by a given antenna, crosses the intracranial region, and received by the remaining 8 antennae. A complete measurement consists of one cycle with each antenna serving as the transmitting antenna. It was hypothesized that HE of 3 ml would be detected by the device.
Ten ICH subjects admitted within 24 hours of stroke onset were enrolled. All patients received a diagnostic head CT (baseline), and a repeat head CT at 12 (+/-6) hours. ICH volumes were determined by blinded neuroradiologist reading, and a significant HE from baseline was considered ≥ 3 ml. Subjects were scanned with the device every 10 minutes for up to 72 hours.
Data from one subject was lost from operator error. Among the remaining nine, two experienced HE of ≥ 3ml (3 and 8.2 ml respectively). SENSE device readings were 100% concordant with the CT scan results.
Competing Interest Statement
JK is an employee of and owns shares of SENS Diagnostics, Inc. GJ, OA and ML are co-inventors of a patent underlying the SENSE device, and owns shares in SENSE Diagnostics, Inc, WK has no conflicts
Clinical Trial
NCT03038087
Funding Statement
National Science Foundation SBIR Phase II 1632270.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
University of Cincinnati IRB
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Available data are presented in the manuscript
